Latest Breaking News On - Michael szumera - Page 1 : comparemela.com

FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy

FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

David deluciaMichael szumeraFibrogen incExchange commissionDrug administrationGen announces topline resultsAmbulatory duchenne muscularNorth star ambulatory assessmentThane wettigInterim chief executive officerAbout duchenne muscular dystrophyOrphan drug designationFast trackRare pediatric disease designationAnnual reportQuarterly report

FibroGen Reports Second Quarter 2023 Financial Results

FibroGen Reports Second Quarter 2023 Financial Results
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

South africaDavid deluciaMichael szumeraExchange commissionDrug administrationChina health authorityFibrogen incCompany phasePancreatic cancer action network pancan precision promiseGen reports second quarterPancreatic cancer action networkThane wettigInterim chief executive officerKey eventsSecond quarterInterim chief executive

FibroGen Reports Second Quarter 2023 Financial Results

South africaMichael szumeraDavid deluciaExchange commissionChina health authorityCompany phaseDrug administrationPancreatic cancer action network pancan precision promiseFibrogen incGen reports second quarterPancreatic cancer action networkThane wettigInterim chief executive officerKey eventsSecond quarterInterim chief executive

FibroGen Announces Leadership Transition

Appoints Thane Wettig as Interim Chief Executive Officer Wettig succeeds Enrique Conterno and brings over 30 years of global pharmaceutical leadership SAN FRANCISCO, July 25, 2023 FibroGen,.

Jim schoeneckEnrique conternoMeichiel keenanMichael szumeraFibrogen incExchange commissionAlliance management for lilly diabetesWashington university in stGlobenewswire incInterim chief executiveChief executive officerChief commercial officerSpecial advisorFibrogen boardMetabolic franchise headChief marketing officer

FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis

- Study did not meet the primary endpoint- Pamrevlumab was generally safe and well tolerated- ZEPHYRUS-2 Phase 3 study will be discontinued- Company to implement plan to extend cash runway into 2026 SAN FRANCISCO, June 26, 2023 (GLOBE NEWSWIRE) FibroGen, Inc. (NASDAQ: FGEN) today announced topline results from its Phase 3 ZEPHYRUS-1 trial evaluating the safety and efficacy of pamrevlumab in patients with idiopathic pulmonary fibrosis (IPF). The study compared treatment with pamrevlumab to pla

Michael szumeraMeichiel keenanEnrique conternoMarkd eisnerPancreatic cancer action networkDrug administrationExchange commissionCorporate communicationsFibrogen incChief medical officerPrecision promiseChief executive officerIdiopathic pulmonary fibrosisOrphan drug designationFast trackRare pediatric disease designation